Mõned tänased analüütikute kommentaarid Euroopas:<br/><br/><b>Coloplast </b>Decline Overdone, Credit Suisse, Barclays Say (Close Dkr456,1)<br/>• Credit Suisse, Barclays advise clients to buy Coloplast shrs after yday’s 5% decline post-3Q results. <br/>• Barclays note says stock hadn’t closed in DKK450s since May 6, day before 2Q results<br/>• Despite 3Q earnings miss, fundamentals remain in tact, guidance attainable<br/>• Credit Suisse (outperform, PT Dkr 495) says results show co. making progress in U.S., emerging markets<br/><b>Land Securities</b> Raised to Buy vs Neutral at BofAML <br/><b>British Land </b>Raised to Buy vs Neutral at BofAML <br/><b>Holcim </b>Raised to Strong Buy vs Outperform at Raymond James <br/><b>Swiss Life</b> Cut to Neutral vs Overweight at JPMorgan; PT 260 to 244 (Close 226)<br/><b>Meda </b>Raised to Strong Buy vs Buy at Swedbank; Pt 135 to 130 (Close 93,0)<br/><b>Baloise </b>Raised to Overweight vs Underweight at JPMorgan; Pt 101 to 129 (Close 113,1)<br/><b>Tvn </b>Added to Goldman Ceemea Focus List, Reiterates Buy ; PT 16,5 to 19,5 (Close 13,75) <br/><b>Essilor </b>Reinstated Neutral at Goldman, PT Eu78.4 (Close 72,25) <br/><b>Adidas </b>Cut to Neutral vs Buy at Goldman; Pt 77,5 to 73,4 (Close 58,65)<br/><b>Luxottica </b>Raised to Neutral vs Sell at Goldman; PT 37,3 to 43,7 (Close 40,19) <br/><b>LVMH </b>Cut to Neutral vs Buy at Goldman; Pt 184 to 158,3 (Close 128,5)<br/><b>Enel </b>Potential Upside In Line With Sector Avg; Raised to neutral from sell at Goldman; PT from Eu4,05 to Eu4,5 (Close 3,9)<br/>• Says recent outperformance mainly linked to falling sovereign risk. <br/>• Says PT implies 15% potential upside, broadly in line with sector avg<br/>• Shrs trading in line with their historical avg P/E discount to sector on 2014 (~25%); says justified by below-sector-avg div. yld (3.5%-5.8% in 2014-18 vs sector avgs of 4.6%-6.3%) and lower EPS growth profile (2014-18 EPS <b>CAGR </b>+5.8% vs sector avg of +7.4%)<br/><b>Kering </b>Cut to Sell vs Neutral at Goldman; Pt 178 to 156,4 (Close 157,15) <br/><b>Moncler </b>Raised to Buy vs Neutral at Goldman; Pt 15 to 16,4 (Close 11,99) <br/><b>Buzzi Unicem</b> Offers Significant Upside, Raised to overweight from equalweight at Morgan Stanley; PT from Eu12,9 to 13,75 (Close 10,76)<br/>• Highlights shrs suffered from concerns about effects of Ukraine crisis on mkts of Ukraine and Russia. <br/>• Says trend intensified recently after new economic sanctions against Russia<br/>• Says Morgan Stanley extreme scenario for Russia (with volumes falling by 25% and real prices by 30%) tests shrs (scenario would result in price target of EU11.75), indicating downside protection<br/>• Says valuation increasingly attractive<br/><b>Siemens </b>Added to Credit Suisse Europe & Global Focus List; PT from 112 to 115 (Close 90,73)<br/>• Balance sheet strength not given enough credit: We believe the market is overly worried about Siemens pursuing overpriced M&A activities while overlooking further divestment potential and its new incentive structure towards a stronger returns focus. On our estimates, Siemens has potential excess kapital of .6-18bn over the next two fiscal years to raise capital allocation measures (beyond the remaining .3.3bn target until FY15) or targeted market expansion (e.g. into Process markets).<br/>• Valuation discount to peers unjustified: We believe core businesses within Siemens' portfolio (e.g. Industry, Power Generation) are now trading at a 40-50% discount to key peers, which is unjustified. Siemens group is currently trading on 7.6x FY15E EV/EBITA implying a 15% discount to its European Electrical peers (35% discount to US Electricals) while having the strongest industrial balance sheet. On our estimates, Siemens trades on an industrial FCF yield of 8.5%.<br/>• Consensus too bearish on margin recovery potential: We believe Siemens can reach clean margins of 12.8% in FY16 (~90bps above consensus) driven by focus on productivity measures (.5.5bn by FY16) and headcount reduction (.1bn). In our view, the risk reward looks very favourable given that our margin bull case is 350bps above consensus while our bear case only 150bps below.<br/><b>Infineon </b>Raised to Buy vs Neutral at UBS <br/><b>Glencore </b>Cut to Neutral vs Outperform at Credit Suisse; PT 380p (Close 365,5)<br/>• We downgrade to Neutral following strong performance YTD (up 20%, +12% relative to sector). GLEN has benefited from its non-iron ore commodity mix and we continue to favour the company's base metal exposure over the medium term, but we now see three near term headwinds: 1) commodity momentum may fade in H2 and the relative call in the short term between base metals and bulks is less clear cut; it may be a year too early before we see a sustained recovery in thermal coal and higher copper prices; 2) earnings have not kept pace with performance and we see over 10% downside risk to consensus for 2015; 3) valuation is now at a premium to peers with only modest upside to our unchanged £3.8 TP.<br/><b>Melexis </b>Rated New Neutral at UBS, PT Eu35 (Close 34,0) <br/><b>Energa </b>Cut to Neutral vs Buy at UBS <br/><b>Kazmunaigaz </b>Cut to Neutral vs Buy at Goldman; Pt 21,3 (Close 18,1)<br/><b>Rosneft </b>Cut to Neutral vs Buy at Goldman; PT 9,9 to 7,7 (Close 6,19) <br/><b>Solocal </b>Removed From Goldman Conviction Buy List, Stays Buy; Pt 1,42 to 0,75 (Close 0,54)<br/><b>Enel </b>Raised to Neutral vs Sell at Goldman; Pt 4,05 to 4,5 (Close 3,9)<br/><b>Intertek </b>Cut to Neutral vs Buy at Goldman; Pt 3240p (Close 2822) <br/><b>Berendsen </b>Cut to Neutral vs Buy at Goldman; Pt 1180p (Close 1055p)<br/><b>Friends Life Group</b> Cut to Neutral vs Buy at Goldman; Pt 330p (Close 312,1p) <br/><b>Dialog Semi </b>Rated Equalweight at Morgan Stanley; PT Eu19 (Close 21,1) <br/><b>Drax </b>Cut to Underperform vs Market Perform at Bernstein; Pt 720 to 550 (Close 645)<br/><b>Drax Group </b>Cut to Neutral vs Overweight at HSBC